research and development of cortisol modulators

Corcept Therapeutics is a biopharmaceutical company focused on modulating cortisol activity at the glucocorticoid receptor (GR) to treat serious diseases. It has discovered more than 1,000 selective proprietary cortisol modulators and received FDA approval in 2012 of Korlym (mifepristone), the first approved treatment for hypercortisolism (Cushing syndrome). It conducts more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology.

Read more

clinical trials